Carisbamate
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
(S)-2-O-carbamoyl-1-o-chlorophenyl-ethanol
|
|
| Identifiers | |
| CAS Number | 194085-75-1  |
| ATC code | N03AX19 (WHO) |
| PubChem | CID 9942577 |
| ChemSpider | 8118189 |
| UNII | P7725I9V3Z |
| ChEMBL | CHEMBL2087003  |
| Chemical data | |
| Formula | C9H10ClNO3 |
| Molar mass | 215.633 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (what is this?) (verify) |
|
Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug under development by Johnson & Johnson Pharmaceutical Research and Development. In 1998, the compound was in-licensed from SK Corp. (currently Life Science Business Division of SK Holdings), a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase III clinical trial for the treatment of partial seizures. Its mechanism of action is unknown.[1][2]
On October 24, 2008, Johnson & Johnson announced that it had submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for carisbamate.[3] Carisbamate has received provisional approval by the FDA to be marketed under the brand name of Comfyde. However, on August 21, 2009, Johnson & Johnson reported that the FDA had failed to give marketing approval.
A double-blind, placebo-controlled trial cf carisbamate in 323 patients with migraine failed to demonstrate that the active drug was more effective than placebo.[4] However, carisbamate was well tolerated at doses up to 600 mg/day.
References[edit]
- ^ Rogawski MA (2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Res. 69 (3): 273–294. doi:10.1016/j.eplepsyres.2006.02.004. PMC 1562526
. PMID 16621450. - ^ Novak GP, Kelley M, Zannikos P, Klein B (2007). "Carisbamate (RWJ-333369)". Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 4 (1): 106–109. doi:10.1016/j.nurt.2006.11.016. PMID 17199023.
- ^ "Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate" (Press release). Johnson & Johnson. 2008-10-24. Retrieved 2008-11-02.
- ^ Cady RK, Mathew N, Diener HC, Hu P, Haas M, Novak GP, Study Group (2009). "Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial". Headache. 49 (2): 216–226. doi:10.1111/j.1526-4610.2008.01326.x. PMID 19222595.
 |
This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |
